Outcomes after HSCT: univariate analysis
| . | Full intensity . | RIC . | P* . | ||
|---|---|---|---|---|---|
| No. evaluated . | Probability (95% CI) . | No. evaluated . | Probability (95% CI) . | ||
| Hematopoietic (neutrophil) recovery at 100 days | 1388 | 96 (95-97) | 92 | 98 (94-100) | .18 |
| Acute GVHD at 100 days (grade II-IV) | 1427 | 46 (43-49) | 93 | 39 (29-49) | .16 |
| Chronic GVHD at 3 y | 1357 | 42 (39-44) | 90 | 34 (24-44) | .16 |
| Treatment-related mortality | 1409 | 92 | |||
| 1 y | 29 (26-31) | 26 (18-36) | .66 | ||
| 3 y | 33 (31-36) | 32 (23-43) | .86 | ||
| Relapse | 1409 | 92 | |||
| 1 y | 19 (17-21) | 26 (17-35) | .15 | ||
| 3 y | 26 (23-28) | 35 (25-46) | .08 | ||
| DFS at 3 y | 1409 | 41 (38-44) | 92 | 32 (22-43) | .12 |
| OS at 3 y | 1428 | 43 (40-46) | 93 | 38 (28-49) | .39 |
| . | Full intensity . | RIC . | P* . | ||
|---|---|---|---|---|---|
| No. evaluated . | Probability (95% CI) . | No. evaluated . | Probability (95% CI) . | ||
| Hematopoietic (neutrophil) recovery at 100 days | 1388 | 96 (95-97) | 92 | 98 (94-100) | .18 |
| Acute GVHD at 100 days (grade II-IV) | 1427 | 46 (43-49) | 93 | 39 (29-49) | .16 |
| Chronic GVHD at 3 y | 1357 | 42 (39-44) | 90 | 34 (24-44) | .16 |
| Treatment-related mortality | 1409 | 92 | |||
| 1 y | 29 (26-31) | 26 (18-36) | .66 | ||
| 3 y | 33 (31-36) | 32 (23-43) | .86 | ||
| Relapse | 1409 | 92 | |||
| 1 y | 19 (17-21) | 26 (17-35) | .15 | ||
| 3 y | 26 (23-28) | 35 (25-46) | .08 | ||
| DFS at 3 y | 1409 | 41 (38-44) | 92 | 32 (22-43) | .12 |
| OS at 3 y | 1428 | 43 (40-46) | 93 | 38 (28-49) | .39 |
Pointwise P value.